SYDNEY: Tuesday, 28 May 2019: Lyramid Limited (ASX: CDY) is pleased to advise that it has appointed Bart Wuurman as CEO of Lyramid, effective 1 June 2019. Mr Wuurman is an accomplished biotech CEO with over 30 years’ experience in innovative drug development, biotech financing, business development and licensing. He has extensive experience in working with research and development based companies in pharmaceutical product development in several therapeutic areas, including cancer, fibrosis and cardiovascular diseases.
The appointment of Mr Wuurman is in line with Lyramid’s strategy to unlock shareholder value by separating the consumer health and the biotech business. His mandate is to accelerate partnering discussions and explore opportunities to fully exploit the midkine assets. As part of Mr Wuurman’s remuneration package, he will be awarded 2,000,000 options in two tranches subject to the successful licensing, partnering or funding of the midkine clinical development program.
Mr Wuurman has previously executed successful biotech deals including Antisoma in the UK via a successful IPO and Lanthio Pharma in the Netherland via a trade sale. At AM-Pharma, as CEO, he was instrumental in securing a €29 million funding round and a $600 million option deal with Pfizer. In 2015 Mr Wuurman became Managing Director of DDF Ventures, a life-science fund with a portfolio of young life sciences companies.
Lyramid CEO, Maria Halasz said “We welcome Bart to the Lyramid leadership team and are very excited to work with him on the midkine portfolio. He has a track record of leading successful commercial deals in biotech and we see many opportunities for value creation in taking our midkine assets to the next level of clinical development.”
T +612 9221 6830 email@example.com
|Investor Relations & Media
T + 61 417 382 391
Lyramid Limited (ASX: CDY)
Lyramid is an Australian life sciences company with a consumer health business and biotech assets in development. Advangen is Lyramid’s wholly owned subsidiary engaged in the development and sale of first in class, best in class, clinically validated anti-aging products for hair, skin and body. Advangen has a range of FGF5 inhibitor hair growth products which are sold in Australia, Japan, USA and China. Advangen has a rich portfolio of hair growth and antiaging hair care assets which include formulations of products on market, trademarks, patents and patent applications, proprietary assays and manufacturing processes. For further information, please see www.lyramid.com.au and www.myevolis.com.au.
Lyramid also has two wholly owned subsidiaries, Lyramid and Kinera, which develop innovative novel therapies and diagnostic tests for fibrotic diseases, cancer and ischemic diseases of the heart. Lyramid holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) globally.
Forward looking statements
This announcement may have forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Lyramid to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as the availability of resources, regulatory environment, the results of marketing and sales activities and competition.